It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
TFX’s FA Score shows that 1 FA rating(s) are green whileTNDM’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
TFX’s TA Score shows that 5 TA indicator(s) are bullish while TNDM’s TA Score has 4 bullish TA indicator(s).
TFX (@Pharmaceuticals: Other) experienced а +2.20% price change this week, while TNDM (@Medical/Nursing Services) price change was -3.65% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.53%. For the same industry, the average monthly price growth was -0.29%, and the average quarterly price growth was +4.24%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +1.37%. For the same industry, the average monthly price growth was +2.38%, and the average quarterly price growth was +4.58%.
TFX is expected to report earnings on Oct 23, 2025.
TNDM is expected to report earnings on Oct 29, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+1.37% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
TFX | TNDM | TFX / TNDM | |
Capitalization | 5.33B | 731M | 730% |
EBITDA | 601M | -152.12M | -395% |
Gain YTD | -31.653 | -69.961 | 45% |
P/E Ratio | 28.13 | N/A | - |
Revenue | 3.04B | 983M | 309% |
Total Cash | N/A | 369M | - |
Total Debt | 2B | 493M | 405% |
TFX | TNDM | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 28 Undervalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 84 | 98 | |
PRICE GROWTH RATING 1..100 | 63 | 97 | |
P/E GROWTH RATING 1..100 | 88 | 94 | |
SEASONALITY SCORE 1..100 | n/a | 19 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TFX's Valuation (28) in the Medical Specialties industry is significantly better than the same rating for TNDM (99). This means that TFX’s stock grew significantly faster than TNDM’s over the last 12 months.
TFX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as TNDM (100). This means that TFX’s stock grew similarly to TNDM’s over the last 12 months.
TFX's SMR Rating (84) in the Medical Specialties industry is in the same range as TNDM (98). This means that TFX’s stock grew similarly to TNDM’s over the last 12 months.
TFX's Price Growth Rating (63) in the Medical Specialties industry is somewhat better than the same rating for TNDM (97). This means that TFX’s stock grew somewhat faster than TNDM’s over the last 12 months.
TFX's P/E Growth Rating (88) in the Medical Specialties industry is in the same range as TNDM (94). This means that TFX’s stock grew similarly to TNDM’s over the last 12 months.
TFX | TNDM | |
---|---|---|
RSI ODDS (%) | 3 days ago73% | 3 days ago78% |
Stochastic ODDS (%) | 3 days ago73% | 3 days ago74% |
Momentum ODDS (%) | 3 days ago52% | 3 days ago82% |
MACD ODDS (%) | 3 days ago53% | 3 days ago75% |
TrendWeek ODDS (%) | 3 days ago52% | 3 days ago83% |
TrendMonth ODDS (%) | 3 days ago51% | 3 days ago83% |
Advances ODDS (%) | 5 days ago54% | 5 days ago77% |
Declines ODDS (%) | 3 days ago74% | 7 days ago81% |
BollingerBands ODDS (%) | 3 days ago86% | 3 days ago69% |
Aroon ODDS (%) | 3 days ago75% | 3 days ago90% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
LSIUX | 13.33 | 0.08 | +0.60% |
ClearBridge International Value IS | |||
DEMRX | 26.38 | 0.11 | +0.42% |
Macquarie Emerging Markets R | |||
HNRGX | 27.30 | N/A | N/A |
Hennessy Energy Transition Investor | |||
CAMLX | 50.85 | -0.15 | -0.29% |
Congress Large Cap Growth Retail | |||
EZTGX | 55.21 | -0.19 | -0.34% |
Eaton Vance Tx-Mgd Growth 1.2 C |
A.I.dvisor indicates that over the last year, TNDM has been loosely correlated with TFX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if TNDM jumps, then TFX could also see price increases.
Ticker / NAME | Correlation To TNDM | 1D Price Change % | ||
---|---|---|---|---|
TNDM | 100% | +1.50% | ||
TFX - TNDM | 45% Loosely correlated | -0.40% | ||
CLPT - TNDM | 40% Loosely correlated | -1.11% | ||
SHC - TNDM | 40% Loosely correlated | -0.13% | ||
AZTA - TNDM | 39% Loosely correlated | -0.65% | ||
A - TNDM | 38% Loosely correlated | +0.28% | ||
More |